Pédiatrie Tumeurs solides CPZP034X2203 (VEG116731) A Phase II Study of Pazopanib GW786034, NSC# 737754 in Children, Adolescents and Young Adults With Refractory Solid Tumors. Paris ISABELLE AERTS
Sarcomes EORTC-1447- STBSG Maintenance Therapy With Trabectedin Versus Observation After First Line Treatment With Doxorubicin of Patients With Advanced or Metastatic Soft Tissue Sarcoma. Paris SOPHIE PIPERNO-NEUMANN
Sein métastatique HER2+ HER2CLIMB (ONT-380-206) Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) Paris
Gynécologie - Ovaires OReO A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy. Paris, Saint-Cloud
Sein métastatique RH+ PADA-1 Randomized, Open Label, Multicentric Phase III Trial to Evaluate the Safety and Efficacy of Palbociclib in Combination With HTdriven by ctDNA ESR1 Mutation Monitoring in ER+, HER2-negative Metastatic Breast Cancer Patients. Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD
Gynécologie - Ovaires PiSARRO p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin/Pegylated Liposomal Doxorubicin Combination Chemotherapy With or Without APR-246. Paris PAUL-HENRI COTTU
Sein métastatique RH+ SAFIR PI3K A Phase II Randomized Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy as Maintenance Therapy in Patients With PIK3CA Mutated Advanced Breast Cancer Paris, Saint-Cloud
Sein métastatique RH+ SAFIR-TOR Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women. Paris, Saint-Cloud PAUL-HENRI COTTU
Recherches "plusieurs pathologies" SHIVA02 (IC 2016-06) Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control. Paris, Saint-Cloud CHRISTOPHE LE TOURNEAU
Sein métastatique HER2+ SOPHIA (CP-MGAH22-04) A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment. Paris, Saint-Cloud ETIENNE BRAIN